146
Antigen-Specific Tolerizing Treatment for Multiple Sclerosis
University of Florida
Nanoparticle
CNS disease
Hit To Lead or Lead Optimization
• Dual-sized, polymeric microparticles (dMPs) loaded with specific antigen and tolerizing factors for intra- and extra-cellular delivery, designed to recruit and modulate dendritic cells toward a tolerogenic phenotype without systemic release.
• Inventors have developed antigen-specific, tolerizing treatment for MS. This is a combinatorial dual-sized MP system (dMP), encapsulating, MS specific antigens and agents selected for their capacity to modulate DC function: both through intracellular delivery of agents in phagocytosable small MPs, and subcutaneous local deposition of agents for controlled release in MPs too large to phagocytose.
• Disease blocking in mouse model of MS was associated with a reduction of infiltrating CD4+ T cells, inflammatory cytokineproducing pathogenic CD4+ T cells, and activated macrophages and microglia in the central nervous system.
• CD4+ T cells isolated from dMP-treated mice were anergic in response to disease-specific, antigen-loaded splenocytes.
• The efficacy of localized microparticle-based drug delivery to mediate antigen-specific tolerance to block MS without global immunosuppression.
WO2020010221A1
• Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases - Multiple Sclerosis and Type 1 Diabetes. Adv Healthc Mater. (2020)
• Treatment with an antigen-specific dual microparticle system reverses advanced multiple sclerosis in mice. PNAS. (2022)
